Patterns of practice and pharmacoeconomic analysis of the management of patients with metastatic renal cell carcinoma (mRCC) in Greece––the CRISIS study. A retrospective analysis by the Hellenic Genitourinary Cancer Group (HGUCG)

ABSTRACT

Background:Metastatic RCC (mRCC) treatment has been revolutionized with 11 approved targeted agents. We report patterns of practice, outcomes and pharmacoeconomic analyses after the introduction of targeted therapy.

Patients and methods: CRISIS was a retrospective multicenter study of mRCCpatients who received targeted therapy . Results were related to the start of 1st-line therapy, with a cut off at 1 January 2011 in order to depict the impact of increased availability of effective options.

Results: 164 patients, were included. 70.1% and 44.5% received 2nd and 3rd-line therapy, respectively. More patients were treated in 2nd-line after 1 January 2011. After a median follow-up of 55.1 months, median progression-free (PFS) and overall survival (OS) were 10.7 (95% confidence intervals [CI]: 8.3–13.7), 7.3 (95% CI: 5.1–8.6), 5.8 (95% CI: 3.8–7.8) and 34 (95% CI: 28.5–39.8), 22.4 (95% CI: 16–32.1), 18.3 (95% CI: 12.4–26.4) months for first, second and third line, respectively. Efficacy of sunitinib and pazopanib in 1st-line were similar. The mean total cost/patient was 35,012.2 Euros (standard deviation [SD]: 28,971.5).

Conclusions: Our study confirms previous real-world data suggesting that continuing advances in the treatment of mRCC produce favorable outcomes in everyday practice. Pharmacoeconomic analyses are important for cost-effective utilization of emerging novel therapies.

KEYWORDS:

• Greece
• Hellenic Genitourinary Cancer Group-HGUCG
• metastatic RCC
• pharmacoeconomic analysis
• targeted therapy

Supplemental Material

The supplementary data for this article can be accessed here

Declaration of interest

G. Tsironis Honoraria: Merck. K. Koutsoukos Honoraria: BMS, MSD, Novartis, Pfizer. A. Visvikis Honoraria: BMS. E. Kostouros Honoraria: Pfizer, Janssen, Novartis, Sanofi- Aventis, BMS, IPSEN, E. Samantas Honoraria, advisory services and research support: Merck, MSD, Roche, Genesis, BMS.

C. Christodoulou Honoraria, advisory services and research support: Roche,Genesis, Pfizer, Novartis, MSD, BMS, Astra Zeneca, Eli Lilly. Travel, accommodations, expenses: Astra Zeneca, Sanofi. M.A. Dimopoulos Honoraria, advisory services and research support: Amgen, Takeda, Celgene, BMS, Janssen. A. Bamias Honoraria, advisory services and research support: Novartis, Ipsen, Pfizer, Roche, MSD. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript other than those disclosed.

Reviewer disclosures

Peer reviewers on this manuscript have no relevant financial or other relationships to disclose.

Author contributions

(I) Conception and design: A. Bamias. K. Tzannis K. Athanasakis, (II) Collection analysis and interpretation of the data: All Authors, (III) Drafting of the paper: G. Tsironis, K. Koutsoukos, K. Athanasakis, K. Tzannis, A. Bamias (IV) Critical Revision of the paper for intellectual content: All Authors, (V) Final approval: All authors. All authors agree to be accountable for all aspects of the work.

Correction Statement

This article has been republished with minor changes. These changes do not impact the academic content of the article.

Additional information

Funding

The study was sponsored by the Hellenic Genitourinary Cancer Group (HGUCG) and supported by a grant from Novartis (formerly GlaxoSmithKline). The company did not participate in the data collecting or management, statistical analysis or interpretation of the results.